Abstract
Acute myeloid leukemia (AML) remains a therapeutic challenge despite increasing knowledge about the molecular origins of the disease, as the mechanisms of AML cell escape from chemotherapy remain poorly defined. We hypothesized that AML cells are addicted to molecular pathways in the context of chemotherapy and used complementary approaches to identify these addictions. Using novel molecular and computational approaches, we performed genome-wide short-hairpin RNA screens to identify proteins that mediate AML cell fate after cytarabine exposure; gene expression profiling of AML cells exposed to cytarabine to identify genes with induced expression in this context; and examination of existing gene expression data from primary patient samples. Integration of these independent analyses strongly implicates cell-cycle checkpoint proteins, particularly WEE1, as critical mediators of AML cell survival after cytarabine exposure. Knockdown of WEE1 in a secondary screen confirmed its role in AML cell survival. Pharmacologic inhibition of WEE1 in AML cell lines and primary cells is synergistic with cytarabine. Further experiments demonstrate that inhibition of WEE1 prevents S-phase arrest induced by cytarabine, broadening the functions of WEE1 that may be exploited therapeutically. These data highlight the power of integrating functional and descriptive genomics, and identify WEE1 as a potential therapeutic target in AML.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Deschler B, Lubbert M . Acute myeloid leukemia: epidemiology and etiology. Cancer 2006; 107: 2099–2107.
Pui CH, Carroll WL, Meshinchi S, Arceci RJ . Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011; 29: 551–565.
Gilliland DG, Tallman MS . Focus on acute leukemias. Cancer Cell 2002; 1: 417–420.
Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453–474.
Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009; 361: 1249–1259.
Burnett AK, Hills RK, Milligan DW, Goldstone AH, Prentice AG, McMullin MF et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol 2010; 28: 586–595.
Lange BJ, Smith FO, Feusner J, Barnard DR, Dinndorf P, Feig S et al. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood 2008; 111: 1044–1053.
Lowenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med 2011; 364: 1027–1036.
Garcia-Carbonero R, Ryan DP, Chabner BA . Cytidine analogs. In: Chabner BA, Longo DL (ed). Cancer Chemotherapy and Biotherapy, Principles and Practice, 3rd edn. Lippincott Williams and Wilkins: Philadelphia, PA, USA, 2001.
Kornblau SM, Qiu YH, Bekele BN, Cade JS, Zhou X, Harris D et al. Studying the right cell in acute myelogenous leukemia: dynamic changes of apoptosis and signal transduction pathway protein expression in chemotherapy resistant ex-vivo selected ‘survivor cells’. Cell Cycle 2006; 5: 2769–2777.
Druker BJ . Translation of the Philadelphia chromosome into therapy for CML. Blood 2008; 112: 4808–4817.
Gregory MA, Phang TL, Neviani P, Alvarez-Calderon F, Eide CA, O’Hare T et al. Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell 2010; 18: 74–87.
Huang S, Laoukili J, Epping MT, Koster J, Holzel M, Westerman BA et al. ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. Cancer Cell 2009; 15: 328–340.
Schlabach MR, Luo J, Solimini NL, Hu G, Xu Q, Li MZ et al. Cancer proliferation gene discovery through functional genomics. Science 2008; 319: 620–624.
Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009; 462: 108–112.
Scholl C, Frohling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009; 137: 821–834.
Luo B, Cheung HW, Subramanian A, Sharifnia T, Okamoto M, Yang X et al. Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci USA 2008; 105: 20380–20385.
Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009; 137: 835–848.
Porter CC, DeGregori J . Interfering RNA-mediated purine analog resistance for in vitro and in vivo cell selection. Blood 2008; 112: 4466–4474.
Robinson MD, McCarthy DJ, Smyth GK . edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010; 26: 139–140.
He Z, Zhou J . Empirical evaluation of a new method for calculating signal-to-noise ratio for microarray data analysis. Appl Environ Microbiol 2008; 74: 2957–2966.
Rhodes DR, Anstett M . Data processing and normalization. 2010. https://support.oncomine.com (accessed on 4 April 2011).
Rhodes DR, Anstett M . Computing fold change. 2010. https://support.oncomine.com (accessed on 4 April 2011).
Chou TC, Talalay P . Quantitative analysis of dose–effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27–55.
Li FX, Zhu JW, Hogan CJ, DeGregori J . Defective gene expression, S phase progression, and maturation during hematopoiesis in E2F1/E2F2 mutant mice. Mol Cell Biol 2003; 23: 3607–3622.
Saldanha AJ . Java Treeview—extensible visualization of microarray data. Bioinformatics 2004; 20: 3246–3248.
de Hoon MJ, Imoto S, Nolan J, Miyano S . Open source clustering software. Bioinformatics 2004; 20: 1453–1454.
Drexler HG, Quentmeier H, MacLeod RA . Malignant hematopoietic cell lines: in vitro models for the study of MLL gene alterations. Leukemia 2004; 18: 227–232.
Quentmeier H, Reinhardt J, Zaborski M, Drexler HG . FLT3 mutations in acute myeloid leukemia cell lines. Leukemia 2003; 17: 120–124.
Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006; 124: 1283–1298.
Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004; 6: 1–6.
Andersson A, Ritz C, Lindgren D, Eden P, Lassen C, Heldrup J et al. Microarray-based classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status. Leukemia 2007; 21: 1198–1203.
Stegmaier K, Ross KN, Colavito SA, O’Malley S, Stockwell BR, Golub TR . Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation. Nat Genet 2004; 36: 257–263.
Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004; 350: 1617–1628.
Parker LL, Piwnica-Worms H . Inactivation of the p34cdc2–cyclin B complex by the human WEE1 tyrosine kinase. Science 1992; 257: 1955–1957.
Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 2009; 8: 2992–3000.
Indovina P, Giordano A . Targeting the checkpoint kinase WEE1: selective sensitization of cancer cells to DNA-damaging drugs. Cancer Biol Ther 2010; 9: 523–525.
Banker DE, Groudine M, Willman CL, Norwood T, Appelbaum FR . Cell cycle perturbations in acute myeloid leukemia samples following in vitro exposures to therapeutic agents. Leuk Res 1998; 22: 221–239.
Vassin VM, Anantha RW, Sokolova E, Kanner S, Borowiec JA . Human RPA phosphorylation by ATR stimulates DNA synthesis and prevents ssDNA accumulation during DNA-replication stress. J Cell Sci 2009; 122 (Part 22): 4070–4080.
Fang F, Newport JW . Evidence that the G1–S and G2–M transitions are controlled by different cdc2 proteins in higher eukaryotes. Cell 1991; 66: 731–742.
Sebastian B, Kakizuka A, Hunter T . Cdc25M2 activation of cyclin-dependent kinases by dephosphorylation of threonine-14 and tyrosine-15. Proc Natl Acad Sci USA 1993; 90: 3521–3524.
Gu Y, Rosenblatt J, Morgan DO . Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J 1992; 11: 3995–4005.
Booher RN, Holman PS, Fattaey A . Human Myt1 is a cell cycle-regulated kinase that inhibits Cdc2 but not Cdk2 activity. J Biol Chem 1997; 272: 22300–22306.
Holzel M, Huang S, Koster J, Ora I, Lakeman A, Caron H et al. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 2010; 142: 218–229.
Hattori H, Zhang X, Jia Y, Subramanian KK, Jo H, Loison F et al. RNAi screen identifies UBE2D3 as a mediator of all-trans retinoic acid-induced cell growth arrest in human acute promyelocytic NB4 cells. Blood 2007; 110: 640–650.
Sampath D, Cortes J, Estrov Z, Du M, Shi Z, Andreeff M et al. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 2006; 107: 2517–2524.
Liejen S, Schellens JH, Shapiro G, Pavlick AC, Tibes R, Demuth T et al. A phase I pharmacological and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. J Clin Oncol 2010; 28 Abstract: 15s.
McGowan CH, Russell P . Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15. EMBO J 1993; 12: 75–85.
Kiviharju-af Hallstrom TM, Jaamaa S, Monkkonen M, Peltonen K, Andersson LC, Medema RH et al. Human prostate epithelium lacks Wee1A-mediated DNA damage-induced checkpoint enforcement. Proc Natl Acad Sci USA 2007; 104: 7211–7216.
Wroble BN, Finkielstein CV, Sible JC . Wee1 kinase alters cyclin E/Cdk2 and promotes apoptosis during the early embryonic development of Xenopus laevis. BMC Dev Biol 2007; 7: 119.
Cools T, Iantcheva A, Weimer AK, Boens S, Takahashi N, Maes S et al. The Arabidopsis thaliana checkpoint kinase WEE1 protects against premature vascular differentiation during replication stress. Plant Cell 2011; 23: 1435–1448.
Zhou BB, Bartek J . Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 2004; 4: 216–225.
Wang Y, Decker SJ, Sebolt-Leopold J . Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol Ther 2004; 3: 305–313.
Hirai H, Arai T, Okada M, Nishibata T, Kobayashi M, Sakai N et al. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther 2010; 9: 514–522.
Seliger B, Papadileris S, Vogel D, Hess G, Brendel C, Storkel S et al. Analysis of the p53 and MDM-2 gene in acute myeloid leukemia. Eur J Haematol 1996; 57: 230–240.
Faderl S, Kantarjian HM, Estey E, Manshouri T, Chan CY, Rahman Elsaied A et al. The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. Cancer 2000; 89: 1976–1982.
Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, Albitar M . The human MDM-2 oncogene is overexpressed in leukemias. Blood 1993; 82: 2617–2623.
Acknowledgements
We thank Drs Chris T Hittinger and Mark Johnston for input in assay design, and Dr Robert Sclafani for critical review of the manuscript. This work was supported by the Colorado Golfers Against Cancer and the AMC Cancer Fund (CCP, ACT, JD), the Leukemia and Lymphoma Society (JD, CCP), and the NCI through The University of Colorado Cancer Center (3P30CA046934-22S4; CCP).
AUTHOR CONTRIBUTIONS
CCP, SF, VZ, PP and AVL performed experiments. JK, DG and ACT developed the BINGS pipeline. CCP, JK, ACT, DG, CG and JD analyzed and interpreted data. CCP, ACT and JD wrote the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Porter, C., Kim, J., Fosmire, S. et al. Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia. Leukemia 26, 1266–1276 (2012). https://doi.org/10.1038/leu.2011.392
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2011.392
Keywords
This article is cited by
-
Synergistic effect of adavosertib and fimepinostat on acute myeloid leukemia cells by enhancing the induction of DNA damage
Investigational New Drugs (2024)
-
Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia
Cancer Cell International (2023)
-
WEE1 and PARP-1 play critical roles in myelodysplastic syndrome and acute myeloid leukemia treatment
Cancer Cell International (2023)
-
Cyclers’ kinases in cell division: from molecules to cancer therapy
Cell Death & Differentiation (2023)
-
Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies
Cancer Chemotherapy and Pharmacology (2023)